Berendt M J, Saluk P H
Infect Immun. 1976 Oct;14(4):965-9. doi: 10.1128/iai.14.4.965-969.1976.
Lipopolysaccharide (LPS) was shown to prevent tumor growth in BALB/c mice when administered either prior to or after the inoculation of lethal doses of tumor cells. An attempt to elucidate the mechanism of this phenomenon utilizing in vivo protocols was made by the adoptive transfer of tumor protection with peritoneal cells as well as with cell-free peritoneal fluids obtained from non-tumor-bearing, LPS-stimulated syngeneic mice. The in vivo-activated peritoneal cells from LPS-treated mice were capable of adoptively transferring tumor protection at peritoneal cell to tumor cell ratios ranging from 1,000:1 to 100:1. Experiments were also performed that indicate that: (i) LPS exerts no direct toxic or inhibitory effect on the tumor cells, and (ii) that residual LPS present in cell and fluid preparations was not responsible for such protection.
当在接种致死剂量的肿瘤细胞之前或之后给予脂多糖(LPS)时,其可抑制BALB/c小鼠体内的肿瘤生长。我们尝试通过用腹膜细胞以及从未荷瘤、LPS刺激的同基因小鼠获得的无细胞腹膜液进行肿瘤保护的过继转移,利用体内实验方案阐明这一现象的机制。来自LPS处理小鼠的体内活化腹膜细胞能够以1000:1至100:1的腹膜细胞与肿瘤细胞比例过继转移肿瘤保护作用。实验还表明:(i)LPS对肿瘤细胞无直接毒性或抑制作用,以及(ii)细胞和液体制剂中存在的残留LPS对此种保护作用无影响。